Dying values? Does pain matter?

Many established values of palliative care practice (like symptom relief, truth-telling, alleviation of suffering) are based on research done outside of Africa, yet African patients may have different values when it comes to death and dying.  A group of South African researchers sought to find out what processes Xhosa people (a 7.9 million-strong … [Read more...]

Could pain science be becoming fashionable? WCPT announces successful symposia.

The World Congress on Physical Therapy, which will be held in Singapore next May, has just announced the successful proposals for symposia. There were, apparently, a very large number of submissions. However, an intriguing thing has happened - 20% of symposiums are focussed on pain. At first glance, one might think - only 20%? However, if that is … [Read more...]

Spinal manipulative therapy: a slow death by data?

Neil O'Connell 2

I am a recovering manual therapist. In my physio career I have moved from freshly qualified apprentice, eager to learn the secrets of what was sold as a powerful tool, particularly for spinal pain, via what might be classed as a skilled practitioner, certainly in terms of courses attended and assessment hoops jumped through, to someone who now … [Read more...]

It is not just the brain that changes itself – time to embrace bioplasticity?

My mate Dr Mick Thacker, has long been teasing me for being neurocentric. In fact - for being A neurocentric. That is, he attaches this neurocentricity to me not just as a characteristic, but as an identity. Moving on from positions of prejudice first requires understanding and I have slowly come to understand that pain is not an emergent property … [Read more...]

Everything you wanted to know about CENTRAL SENSITISATION

BiM review of a J Pain paper by Alban Latremoliere and Clifford J. Woolf (AKA L&W) By Kerwin Talbot & Lorimer Moseley Another of our series on the Journal of Pain’s most downloaded articles – this one on central sensitisation. There is no doubt that central sensitisation has such a prominent role in our pain lexicon that it almost … [Read more...]

BiM in Review 2013

Here we are again - summer time on top of the world and with the mercury due to top 44C this week, we are well and truly gearing up for scorching days and balmy nights, beach cricket, home-made lemonade and plenty of bubbles. We will be on what I call ‘skeleton presence’ from Christmas Eve until late January. So, as is customary here at BiM, let’s … [Read more...]

Illusory Perceptions

Postman Pat

A person, let’s say his name is Pat, views a staircase in front of him; he is delivering a parcel (Postman Pat) and must climb three flights of stairs to deliver it to flat 15. Pat has knee pain and stairs aggravate his pain. Just as Pat is surveying the stairs, a (pain-free) resident sidles passed him and makes his way up; Pat follows behind him. … [Read more...]

Time to get qualified in Pain Science?

University of Sydney

Information and new findings about pain bombard us from all directions and keeping abreast of them is a major challenge. Another challenge is integrating this knowledge for clinical applications. While there are discipline-specific issues associated with pain and its management, we need to know about the broad field of pain if we are to work … [Read more...]

Generating Much Interest (aka GMI)

Graded motor imagery (GMI) for the treatment of chronic pain has certainly been generating much interest recently. Earlier this year, I was lucky enough to publish a systematic review and meta-analysis - with a pretty snazzy bunch of researchers might I add - looking at the effects of GMI and its components on chronic pain. We published our article … [Read more...]

Potluck? Might Cannabis reduce neuropathic pain?

The Journal of Pain’s 4th most downloaded article in 2013 (Wilsey ey al 2013) is a study of vaporised cannabis for the treatment of neuropathic pain.[1]  Thirty-nine patients, with various types of refractory neuropathic pain, participated in a double-blind crossover study, receiving low-dose (1.29%), medium dose (3.53%) or placebo cannabis in each … [Read more...]